Dysregulation of the insulin/IGF binding protein-1 axis in transgenic mice is associated with hyperinsulinemia and glucose intolerance

Diabetes

Volumn 49, Issue 3, 2000, Pages 457-465

  Crossey, Paul A ^a   Jones, Jennifer S ^a   Miell, John P ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; INSULIN; SOMATOMEDIN C;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; DISEASE ASSOCIATION; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE; HYPERGLYCEMIA; HYPERINSULINEMIA; IMPAIRED GLUCOSE TOLERANCE; INSULIN BLOOD LEVEL; INSULIN RELEASE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; REGULATORY MECHANISM; SEX DIFFERENCE; TRANSGENIC MOUSE;

EID: 0034088143     PISSN: 00121797     EISSN: None     Source Type: Journal    
DOI: 10.2337/diabetes.49.3.457     Document Type: Article

References (35)

1. Sherwin RS, Borg WP, Boulware SD: Metabolic effects of insulin-like growth factor I in normal humans. Horm Res 41 (Suppl. 2):97-101, 1994
2. Jones JI, Clemmons DR: Insulin-like growth factors and their binding proteins: biological actions. Endocr Rev 16:3-34, 1995
3. Baxter RC: Insulin like growth factor binding proteins as glucoregulators. Metabolism 44 (Suppl. 4): 12-17, 1995
4. Pao C-I, Farmer PK, Begovic S, Goldstein S, Wu G-J, Phillips LS: Expression of hepatic insulin-like growth factor-I and insulin-like growth factor-binding protein-1 genes is transcriptionally regulated in streptozotocin-diabetic rats. Mol Endocrinol 6:969-977, 1992
5. Johnson TR, Blossey BK, Denko CW, Ilan J: Expression of insulin like growth factor I in cultured rat hepatocytes: effects of insulin and growth hormone. Mol Endocrinol 3:580-587, 1989
6. Porksen N, Hussain MA, Bianda TL, Nyholm B, Christiansen JS, Butler PC, Veldhuis JD, Froesch ER, Schmitz O: IGF-I inhibits burst mass of pulsatile insulin secretion at supraphysiological and low IGF-I infusion rates. Am J Physiol 272:E352-E358, 1997
7. Zenobi PD, Graf S, Ursprung II, Froesch ER: Effects of insulin-like growth factor-I on glucose tolerance, insulin levels, and insulin secretion. J Clin Invest 89:1908-1913, 1992
8. Moses AC, Young SCJ, Morrow LA, O'Brien M, Clemmons DR: Recombinant human insulin-like growth factor I increases insulin sensitivity and improves glycemic control in type II diabetes. Diabetes 45:91-100, 1990
9. Acerini CL, Harris D, Matyka KA, Watts AP, Umpleby AM, Russell-Jones DL, Dunger DB: Effects of low-dose recombinant human insulin-like growth factor-I on insulin sensitivity, growth hormone and glucagon levels in young adults with insulin-dependent diabetes mellitus. Metabolism 47:1481-1489, 1998
10. Ooi GT, Tseng LY, Tran MQ, Rechler MM: Insulin rapidly decreases insulin-like growth factor-binding protein-1 gene transcription in streptozotocin-diabetic rats. Mol Endocrinol 6:2219-2228, 1992
11. Powell DR, Suwanichkul A, Cubbage ML, DePaolis LA, Snuggs MB, Lee PDK: Insulin inhibits transcription of the human gene for insulin-like growth factor-binding protein-1. J Biol Chem 266:18868-18876, 1991
12. Lewitt MS, Baxter RC: Insulin-like growth factor-binding protein-1: a role in glucose counterregulation. Mol Cell Endocrinol 79:146-152, 1991
13. Munoz MT, Barrios V, Pozo J, Argente J: Insulin-like growth factor I, its binding proteins 1 and 3, and growth hormone-binding protein in children and adolescents with insulin-dependent diabetes mellitus: clinical implications. Ped Res 39:992-998, 1996
14. Clauson P, Brismar K, Grill V: Insulin like growth factor-I and IGF binding protein-1 in a representative NIDDM population (Abstract). Diabetologia 38 (Suppl. 1):A132, 1995
15. Kobayashi K, Amemiya S, Sawanobori E, Higashida K, Ishihara T, Kobayashi K, Kato K, Nakazawa S: Role of IGF binding protein-1 in the dawn phenomenon and glycemic control in children and adolescents with IDDM. Diabetes Care 20:1442-1447, 1997
16. Strasser-Vogel B, Blum WF, Past R, Kessler U, Hoeflich A, Meiler B, Kiess W: Insulin-like growth factor (IGF)-I and -II and IGF-binding proteins-1, -2, and -3 in children and adolescents with diabetes mellitus: correlation with metabolic-control and height attainment. J Clin Endocrinol Metab 80:1207-1213, 1995
17. Rajkumar K, Barron D, Lewitt MS, Murphy IJ: Growth retardation and hyperglycemia in insulin-like growth factor binding protein-1 transgenic mice. Endocrinology 136:4029-4034, 1995
18. Ehrenborg E, Larsson C, Stern I, Janson M, Powell DR, Luthman H: Contiguous localization of the genes encoding human insulin-like growth factor binding proteins 1(IGBP1) and 3 (IGBP3) on chromosome 7. Genomics 12:497-502, 1992
19. Sambrook J, Fritsch EF, Maniatis T: Molecular Cloning: A Laboratory Manual. Cold Spring Harbour, NY, Cold Spring Harbour Laboratory Press, 1989
20. Julkunen M, Koistinen R, Aalto-Setala K, Seppala M, Janne OA, Kontula K: Primary structure of human insulin-like growth factor-binding protein/placental protein 12 and tissue-specific expression of its mRNA. FEBS Lett 236:295-302, 1988
21. Khosravi MJ, Diamandi A, Mistry J: Immunoassay of insulin-like growth factor binding protein-I. Clin Chem 43:523-532, 1997
22. Murphy LJ, Barron D, Seneviratne C: Hormonal regulation of insulin like growth factor binding protein-1 expression and the development of transgenic mouse models to study IGFBP-1 function. In Current Directions in Insulin Like Growth Factor Research. LeRoith D, Raizada R, Eds. New York, Plenum Press, 1994, p. 279-291
23. Busby WH Jr, Klapper DG, Clemmons DR: Purification of a 31,000-dalton insulin-like growth factor binding protein from human amniotic fluid: isolation of two forms with different biologic actions. J Biol Chem 263:14203-14210, 1988
24. Elgin RG, Bushy WH Jr, Clemmons DR: An insulin-like growth factor (IGF) binding protein enhances the biologic response to IGF-I. Proc Natl Acad Sci U S A 84:3254-3258, 1987
25. Koistinen R, Angervo M, Leinonen P, Seppala M: Phosphorylation of insulin-like growth factor-binding protein-1 from different sources. Growth Reg 3:34-37, 1993
26. Westwood M, Gibson JM, Williams AC, Clayton PE, Hamberg O, Flyvbjerg A, White A: Hormonal regulation of circulating insulin-like growth factor-binding protein-1 phosphorylation status. J Clin Endocrinol Metab 80:3520-3527, 1995
27. Horikawa Y, Iwasaki N, Hara M, Furuta H, Hinokio Y, Cockburn BN, Lindner T, Yamagata K, Ogata M, Tomonaga O, Kuroki H, Kasahara T, Iwamoto Y, Bell GI: Mutation in bepatocyte nuclear factor-1 beta gene (TCF2) associated with MODY. Nat Genet 17:384-385, 1997
28. Furuta H, Iwasaki N, Oda N, Hinokio Y, Horikawa Y, Yamagata K, Yano N, Sugahiro J, Ogata M, Ohgawara H, Omori Y, Iwamoto Y, Bell GI: Organization and partial sequence of the hepatocyte nuclear factor-4 alpha/MODY1 gene and identification of a missense mutation, R127W, in a Japanese family with MODY. Diabetes 46:1652-1657, 1997
29. Lithell HO, McKeigue PM, Berglund L, Mohsen R, Lithell UB, Leon DA: Relation of size at birth to non-insulin dependent diabetes and insulin concentrations in men aged 50-60 years. BMJ 17:406-410, 1996
30. Langford K, Blum W, Nicolaides K, Jones J, McGregor A, Miell J: The pathophysiology of the insulin-like growth factor axis in fetal growth failure: a basis for programming by undernutrition? Eur J Clin Invest 24:851-856, 1994
31. Giudice LC, de Zegher F, Gargosky SE, Dsupin BA, de las Fuentes L, Crystal RA, Hintz RL, Rosenfeld RG: Insulin-like growth factors and their binding proteins in the term and preterm human fetus and neonate with normal and extremes of intrauterine growth. J Clin Endocrinol Metab 80:1548-1555, 1995
32. Phipps K, Barker DJP, Hales CN, Fall CHD, Osmond C, Clark PMS: Fetal growth and impaired glucose tolerance in men and women. Diabetologia 36:225-228, 1993
33. Phillips DIW, Barker DJP, Hales CN, First S, Osmond C: Thinness at birth and insulin resistance in adult life. Diabetologia 37:150-154, 1994
34. Rajkumar K, Dheen ST, Murphy LJ: Hyperglycemia and impaired glucose tolerance in IGF binding protein-1 transgenic mice. Am J Physiol 270:E565-E571, 1996
35. Moller DE, Chang PY, Yaspelkis BP, Flier JS, Wallberg-Henriksson H, Ivy JL: Transgenic mice with muscle specific insulin resistance develop increased adiposity, impaired glucose tolerance and dyslipidemia. Endocrinology 137: 2397-2405, 1996